Yes, if you meet NICE eligibility criteria, typically when triple oral therapy for type 2 diabetes is inadequate and specific BMI or comorbidity thresholds apply
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
Known for its clinically curated formulations, advanced delivery systems, and dermatologist-inspired innovation, Becuras expansion into the US reflects its growing global demand for evidence-based skin, hair, and wellness solutions
Initial side effectsnausea, mild fatigue, or injection site reactionsusually diminish within days to weeks as your body adapts
Sato A, Takeda A
PMID: 11045606
